| First Author | Zhang Y | Year | 2020 |
| Journal | FASEB J | Volume | 34 |
| Issue | 12 | Pages | 16364-16382 |
| PubMed ID | 33058355 | Mgi Jnum | J:311325 |
| Mgi Id | MGI:6754211 | Doi | 10.1096/fj.202001271R |
| Citation | Zhang Y, et al. (2020) Selective loss of 5hmC promotes neurodegeneration in the mouse model of Alzheimer's disease. FASEB J 34(12):16364-16382 |
| abstractText | 5-hydroxymethylcytosine (5hmC) is an intermediate stage of DNA de-methylation. Its location in the genome also serves as an important regulatory signal for many biological processes and its levels change significantly with the etiology of Alzheimer's disease (AD). In keeping with this relationship, the TET family of enzymes which convert 5-methylcytosine (5mC) to 5hmC are responsive to the presence of Abeta. Using hMeDIP-seq, we show that there is a genome-wide reduction of 5hmC that is found in neurons but not in astrocytes from 3xTg mice (an AD mouse model). Decreased TET enzymatic activities in the brains of persons who died with AD suggest that this reduction is the main cause for the loss of 5hmC. Overexpression of human TET catalytic domains (hTETCDs) from the TET family members, especially for hTET3CD, significantly attenuates the neurodegenerative process, including reduced Abeta accumulation as well as tau hyperphosphorylation, and improve synaptic dysfunction in 3xTg mouse brain. Our findings define a crucial role of deregulated 5hmC epigenetics in the events leading to AD neurodegeneration. |
